NCT06561685 2026-02-10A Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsEli Lilly and CompanyPhase 1 Recruiting340 enrolled
NCT00949650 2018-04-06BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR MutationBoehringer IngelheimPhase 3 Completed345 enrolled 23 charts 1 FDA